Paediatric Strategy Forums

Paediatric Strategy Forums

Upcoming Forums

13th Paediatric Strategy Forum for diffuse midline gliomas

8-9 May 2024

SickKids, Toronto

14th Paediatric Strategy Forum ON Novel ways to target and enhance efficiency of anti-GD2 therapies

24-25 October 2024

European Medicines Agency, EMA

Submit your Expression of Interest today!

About the Forums


Paediatric Strategy Forums are multi-stakeholder meetings in which strategies regarding new drug development are discussed. Each Forum focuses on either a given paediatric malignancy or the development of a class of compounds with regards to their mechanism of action. These scientific meetings are aimed at facilitating prioritisation in order to better meet the needs of patients and to increase feasibility of paediatric developments.
Suggest new topics
What?
 

A multi-stakeholder Forum where all Stakeholders share information and discuss the strategy of new drug development with regards to their Mechanism of Action (MoA) to address unmet medical needs in a transparent scientific discussion

When?
 

Q1/ Midst/ Q4 every year

Where?
 

2 live Paediatric Strategy Forums – 1 in Europe & 1 in US

 

1 Virtual Paediatric Strategy Forum

Why?
 

To share information, to facilitate the development of innovative medicines and ultimately their introduction into the standard-of-care of children with malignancies

Agreement by all involved (industry and academia) based on scientific arguments

Which product, based on current evidence, is considered to have the highest potential to address unmet medical needs 

The sequence in which other available (or emerging) products should be developed or deferred. So that  as soon as a development is completed (either due to futility or efficacy) others are already prepared for evaluation

Engage regulatory agencies in a consolidated effort early in development

Monitoring changes in regulatory submissions and approvals both in Europe and the US (changing from adult-condition based waivers to scientifically and medically relevant waivers)

Publish results publicly via summaries and manuscripts

Oversight Committee

The ACCELERATE Oversight Committee is a multi-stakeholder committee which is responsible for the choice of topics and proposing dates for the Paediatric Strategy Forums. They identify 2-3 representatives from relevant international cooperative trial groups from both sides of the Atlantic for the preparation of each Forum. The Oversight Committee also monitors the impact of the Forums.

ACCELERATE Steering Commitee
Global Paediatric Cancer Community
Regulators
Patient Advocates
    • 12TH Paediatric Strategy Forum for CDK4/6, CDK 7 and CDK 9 Inhibitors

    26-27 October 2023, Amsterdam

    11TH Paediatric Strategy Forum for PI3K, mTOR and AKT inhibitors

    3-4 April 2023, Boston

    10TH Paediatric Strategy Forum for DNA Damage Pathway Inhibitors

    27-28 October 2022, Amsterdam


    Scientific manuscript: HERE

    9TH PAEDIATRIC STRATEGY FORUM FOR MEDICINAL PRODUCT DEVELOPMENT IN MAPK PATHWAY INHIBITORS

    28 March & 29 March 2022

    Virtual

    • Scientific manuscript: HERE
    8TH PAEDIATRIC STRATEGY FORUM FOR MEDICINAL PRODUCT DEVELOPMENT OF MULTI-TARGETED KINASE INHIBITORS IN BONE SARCOMA

    30 November & 1 December 2021,

    Virtual

    • Scientific manuscript: HERE
    7TH PAEDIATRIC STRATEGY FORUM FOR MEDICINAL PRODUCT DEVELOPMENT OF CAR T-CELLS IN CHILDREN AND ADOLESCENTS

    25-27 May 2021, Virtual


    • Scientific manuscript: HERE
    6th Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies

    13-14 January 2021, Virtual

    • Scientific manuscript: HERE
    5th Paediatric Strategy Forum for Medicinal Product Development of Epigenetic Modifiers in Children and Adolescents

    23-24 January 2020, Philadelphia

    • Public summary: HERE
    • Scientific manuscript: HERE
    4th Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents

    11-12 April 2019, Rotterdam

    • Public summary: HERE
    • Scientific manuscript: HERE
    3rd Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

    5-6 September 2018, EMA, London

    • Public summary: HERE
    • Scientific manuscript: HERE
    2nd Paediatric Strategy Forum for Medicinal product development for mature B-cell malignancies in children

    13-14 November 2017, EMA, London

    • Public summary: HERE
    • Scientific manuscript: HERE
    1st Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies

    30-31 January 2017, EMA, London

    • Public summary: HERE
    Share by: